1. A close relationship betweenHelicobacter pyloriinfection and the serum level of CD47 in adults
   Lei Feng et al, 2020, Scandinavian Journal of Gastroenterology CrossRef
2. Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
   Alexandra Giatromanolaki et al, 2022, Cancers CrossRef
3. Prognostic significance of CKS2 and CD47 expression in patients with gastric cancer who underwent radical gastrectomy
   Yang Zhou et al, 2022, Scandinavian Journal of Immunology CrossRef
4. Targeting HDAC6 improves anti-CD47 immunotherapy
   Maria Gracia-Hernandez et al, 2024, Journal of Experimental & Clinical Cancer Research CrossRef
5. CD47: the next checkpoint target for cancer immunotherapy
   Ridong Feng et al, 2020, Critical Reviews in Oncology/Hematology CrossRef
6. Is CD47 a potentially promising therapeutic target in cardiovascular diseases? — Role of CD47 in cardiovascular diseases
   Quanli Cheng et al, 2020, Life Sciences CrossRef
7. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
   Zi-Han Ye et al, 2023, Acta Pharmaceutica Sinica B CrossRef
8. Hydrogen gas represses the progression of lung cancer via down-regulating CD47
   Jinghong Meng et al, 2020, Bioscience Reports CrossRef
9. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
   Wenting Zhang et al, 2020, Frontiers in Immunology CrossRef
10. The CD47-SIRPα axis is a promising target for cancer immunotherapies
    Yu Hao et al, 2023, International Immunopharmacology CrossRef
11. CD47 is a Novel Potent Immunotherapy Target in Human Malignancies: Current Studies and Future Promises
    Bing Tong et al, 2018, Future Oncology CrossRef
12. Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma
    Ryo Kazama et al, 2020, Cancer Science CrossRef
13. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein α Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library
    Zhihong Wang et al, 2021, Molecular Pharmacology CrossRef
14. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer
    Kaiqi Zhang et al, 2024, Cancer Immunology, Immunotherapy CrossRef
15. Next generation of immune checkpoint inhibitors and beyond
    Julian A. Marin-Acevedo et al, 2021, Journal of Hematology & Oncology CrossRef
16. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor
    Rami Imam et al, 2021, BMC Cancer CrossRef
17. PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
    Zhenlin Yang et al, 2021, Thoracic Cancer CrossRef
18. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor
    Ken Tanaka et al, 2023, Pathology CrossRef
19. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors
    Emmanouil Tzatzarakis et al, 2019, Expert Review of Anticancer Therapy CrossRef